From Biological Insight to a New Class of Medicines for Hemophilia A
The 2026 Lasker-DeBakey Clinical Medical Research Award recognizes researchers who developed a bispecific antibody mimicking blood coagulation factor VIII. The antibody offers a new class of medicines for hemophilia A, a life-threatening bleeding disorder caused by lack of factor VIII. The winners describe how biological insight drove the drug's development.
Why it matters: Lasker award spotlights a bispecific antibody that created a new treatment class for hemophilia A.